...
首页> 外文期刊>Expert opinion on biological therapy >A review of antibody-based therapeutics targeting G protein-coupled receptors: an update
【24h】

A review of antibody-based therapeutics targeting G protein-coupled receptors: an update

机译:靶向G蛋白偶联受体的抗体疗法最新进展

获取原文
获取原文并翻译 | 示例

摘要

Introduction: G protein-coupled receptors (GPCRs) play key roles in many biological functions and are linked to many diseases across all therapeutic areas. As such, GPCRs represent a significant opportunity for antibody-based therapeutics. Areas covered: The structure of the major GPCR families is summarized in the context of choice of antigen source employed in the drug discovery process and receptor biology considerations which may impact on targeting strategies. An overview of the therapeutic GPCR-antibody target landscape and the diversity of current therapeutic programs is provided along with summary case studies for marketed antibody drugs or those in advanced clinical studies. Antibodies in early clinical studies and the emergence of next-generation modalities are also highlighted. Expert opinion: The GPCR-antibody pipeline has progressed significantly with a number of technical developments enabling the successful resolution of some of the challenges previously encountered and this has contributed to the growing interest in antibody-based therapeutics addressing this target class.
机译:简介:G蛋白偶联受体(GPCRs)在许多生物学功能中起着关键作用,并且与所有治疗领域的许多疾病有关。因此,GPCR代表了基于抗体的疗法的重要机会。涵盖的领域:在药物发现过程中使用的抗原来源选择和可能影响靶向策略的受体生物学考虑的背景下,总结了主要 GPCR 家族的结构。本文概述了治疗性GPCR抗体靶点的前景和当前治疗方案的多样性,并总结了已上市抗体药物或处于高级临床研究中的药物的案例研究。还强调了早期临床研究中的抗体和下一代模式的出现。专家意见:GPCR抗体管线取得了重大进展,许多技术发展使人们能够成功解决以前遇到的一些挑战,这有助于对针对这一目标类别的基于抗体的疗法的兴趣日益浓厚。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号